Information Provided By:
Fly News Breaks for September 6, 2019
Sep 6, 2019 | 06:13 EDT
BofA/Merrill analyst Kevin Fischbeck downgraded Mednax to Underperform from Neutral and lowered his price target for the shares to $19 from $32. The company's fundamentals and EBITDA growth remain weak, and it is unlikely to achieve sufficient organic growth to maintain margins, Fischbeck tells investors in a research note. Further, the analyst adds that industry-wide payor mix pressures are bigger for Mednax than any other company he covers.
News For MD From the Last 2 Days
Feb 24, 2020 | 09:08 EST
JPMorgan analyst Gary Taylor lowered the firm's price target on Mednax to $20 from $33 and keeps a Neutral rating on the shares. To calls the company's situation "fluid seems an understatement, but the preponderance of surprise continues to be to the downside," Taylor tells investors in a post-earnings research note.